CBS 2019
CBSMD教育中心
中 文

左主干支架

Abstract

Recommended Article

Quality of Life after Everolimus-Eluting Stents or Bypass Surgery for Treatment of Left Main Disease Provisional versus elective two-stent strategy for unprotected true left main bifurcation lesions: Insights from a FAILS-2 sub-study Impact of Staging Percutaneous Coronary Intervention in Left Main Artery Disease: Insights From the EXCEL Trial Current treatment of significant left main coronary artery disease: A review Expansion or contraction of stenting in coronary artery disease? Complex PCI procedures: challenges for the interventional cardiologist Ten-Year All-Cause Death According to Completeness of Revascularization in Patients With Three-Vessel Disease or Left Main Coronary Artery Disease: Insights From the SYNTAX Extended Survival Study Clinical and angiographic outcomes of patients treated with everolimus-eluting stents or first-generation Paclitaxel-eluting stents for unprotected left main disease
|<<... 4 5 6 7 8 9 10 ...>>|

Clinical TrialAvailable online 30 October 2017

JOURNAL：J Am Coll Cardiol. Article Link

Quality of Life after Everolimus-Eluting Stents or Bypass Surgery for Treatment of Left Main Disease

SJ. Baron, K Chinnakondepalli, EA. Magnuson et al. Keywords: Quality of Life; Left Main Coronary Artery Disease; Percutaneous Coronary Intervention; Bypass Surgery

ABSTRACT

Background - The EXCEL trial compared outcomes in patients with unprotected left main coronary artery disease (LMCAD) treated with coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) using everolimus-eluting stents. While rates of death, stroke, and myocardial infarction were similar at 36 months, event timing and repeat revascularization rates differed by treatment group.


Objectives - To understand the effects of revascularization strategy from the patient’s perspective, we performed a prospective quality of life (QoL) sub-study alongside the EXCEL trial.


Methods - Between September 2010 and March 2014, 1905 patients with LMCAD were randomized to undergo CABG or PCI, of whom 1788 participated in the QoL sub-study. QoL was assessed at baseline and 1, 12, and 36 months using the Seattle Angina Questionnaire, the SF-12, the Rose Dyspnea Scale, the Patient Health Questionnaire-8, and the EQ-5D. Differences between PCI and CABG were assessed using longitudinal random-effect growth curve models.


Results - Over 36 months, both PCI and CABG were associated with significant improvements in QoL compared with baseline. At 1 month, PCI was associated with better QoL than CABG. By 12 months though, these differences were largely attenuated, and by 36 months, there were no significant QoL differences between PCI and CABG.


Conclusions - Among selected patients with LMCAD, both PCI and CABG result in similar QoL improvement through 36 months, although a greater early benefit is seen with PCI. Taken together with the 3-year clinical results of EXCEL, these findings suggest that PCI and CABG provide similar intermediate-term outcomes for patients with LMCAD.

>CBS CBS 2019

> CBS 2019 REGISTRATION

> CBS 2019 PROGRAM

> CBS 2019 CALL FOR SCIENCE

> CBS 2019 SPOTLIGHTS

 CBSMD

> CBSMD WEBSITE REGISTRATION

> EDUCATION CENTER

> RECOMMANDED PAPER

> TOP 10 RESEARCH PAPER

> PRE-READING

CBS 2019 CBS 2019 FACULTY Education Resource CBSMD Scientific Library
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top